Skip to Content
Søg Menu

ASH2020: New Treatment Relapsed/Refractory Mantle Cell Lymphoma – data from phase 1 study

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Related

Dansk studie: Blæk i tatoveringer kan muligvis øge risikoen for lymfom og hudkræft 

/ Signe Bedsted Clemmensen / Jan Andreasen
HudcancerLymfom
Tarec El-galaly

Ingen ændringer i behandlingen inden for lymfom efter ASH 2024, men mange vigtige updates

/ Tarec Christoffer El-Galaly
ASH24Lymfom Play the Video 02:53
Alexander Fuglkjær

Machine learning kan reducere unødvendige indlæggelser af kræftpatienter

/ Alexander Fuglkjær
AIASH24Lymfom Play the Video 01:57
Ingrid Glimelius

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Ingrid Glimelius
ASH24Lymfom Play the Video 01:46
Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Ingrid Glimelius
ASH24Lymfom Play the Video 03:27
Timothy Fenske

The Majority of Patients with Mantle Cell Lymphoma Probably Don’t Need Auto-Transplant in the Current Treatment Era

/ Timothy S. Fenske
ASH24Lymfom Play the Video 05:17
Mats Jerkeman

There Is Definitely A Need for Novel Treatments for Elderly Patients with Mantle Cell Lymphoma

/ Mats Jerkeman
ASH24Lymfom Play the Video 03:13
Martin Dreyling

ECHO Trial Highlights Acalabrutinib’s Promise in Mantle Cell Lymphoma Treatment

/ Martin Dreyling
ASH24Lymfom Play the Video 03:48

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom
Back to top